{"id":16379,"date":"2022-12-08T15:17:32","date_gmt":"2022-12-08T14:17:32","guid":{"rendered":"https:\/\/convergences.online\/hemato\/?p=16379"},"modified":"2024-12-11T18:20:10","modified_gmt":"2024-12-11T17:20:10","slug":"incidence-et-prevalence-de-la-maladie-thromboembolique-veineuse-chez-les-patients-atteints-de-maladie-chronique-du-foie-une-revue-systematique-et-meta-analyse","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/incidence-et-prevalence-de-la-maladie-thromboembolique-veineuse-chez-les-patients-atteints-de-maladie-chronique-du-foie-une-revue-systematique-et-meta-analyse\/","title":{"rendered":"Incidence et pr\u00e9valence de la maladie thromboembolique veineuse chez les patients atteints de maladie chronique du foie\u00a0: une revue syst\u00e9matique et m\u00e9ta-analyse\u2028"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1302px;margin-left: calc(-5% \/ 2 );margin-right: calc(-5% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:2.375%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:2.375%;--awb-width-medium:100%;--awb-spacing-right-medium:2.375%;--awb-spacing-left-medium:2.375%;--awb-width-small:100%;--awb-spacing-right-small:2.375%;--awb-spacing-left-small:2.375%;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><p>R\u00e9f. : HematoStat.net ; 3 (4) : R61<\/p>\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35594737\/\"><i>Incidence and prevalence of venous thromboembolism in chronic liver disease: A systematic review and meta-analysis. Incidence and prevalence of venous thromboembolism in chronic liver disease: A systematic review and meta-analysis. Mohsan Subhani and al. Thromb Res. 2022 Jul;215:19-29. doi: 10.1016\/j.thromres.2022.05.004.<\/i><\/a><\/p>\n<h3>R\u00e9sum\u00e9 de l&#8217;article<\/h3>\n<p>Depuis de nombreuses ann\u00e9es, la coagulopathie associ\u00e9e \u00e0 la cirrhose \u00e9tait suppos\u00e9e \u00eatre \u00e0 l\u2019origine de complications h\u00e9morragiques fr\u00e9quentes et potentiellement fatales. Cependant, les \u00e9v\u00e8nements thrombotiques dus \u00e0 cette coagulopathie demeurent un r\u00e9el risque. Les auteurs de cette \u00e9tude ont r\u00e9alis\u00e9 une revue de la litt\u00e9rature et une m\u00e9ta-analyse afin d\u2019\u00e9valuer l\u2019\u00e9pid\u00e9miologie de la maladie thromboembolique veineuse (MTEV) chez les patients atteints de maladie chronique du foie. Vingt-neuf \u00e9tudes ont \u00e9t\u00e9 analys\u00e9es et ont permis d\u2019\u00e9tudier 19 157 018 patients parmi lesquels 152 049 ont pr\u00e9sent\u00e9 une MTEV (0,79 %). Chez les patients atteints de maladie chronique h\u00e9patique hospitalis\u00e9s, l\u2019incidence cumul\u00e9e de la MTEV \u00e9tait de 1,07 % (IC 95 % : 0,80 \u2013 1,38) par an et le taux d\u2019incidence \u00e9tait de 157,15 (IC 95 % : 14,74 \u2013 445,29) pour 10 000 patients-ann\u00e9es et la pr\u00e9valence \u00e9tait de 1,10 % (IC 95 % 0,80 \u2013 1,38) par an.<\/p>\n<h3>Dans nos pratiques<\/h3>\n<p>Les patients hospitalis\u00e9s et atteints de maladies chronique du foie sont donc \u00e0 risque de d\u00e9velopper une MTEV. Tous les ans, pour 1000 patients hospitalis\u00e9s avec une maladie h\u00e9patique, 10 auront un nouveau diagnostic de MTEV et 11 ont eu un diagnostic pr\u00e9alable de MTEV. Il est donc n\u00e9cessaire d\u2019adapter des strat\u00e9gies anticoagulantes performante chez ces patients, tout en tenant compte de la coagulopathie associ\u00e9es et des comorbidit\u00e9s.<\/p>\n<h3>Regard du biostatisticien<\/h3>\n<p>Les auteurs de cette \u00e9quipe anglaise se sont \u00e9vertu\u00e9s \u00e0 suivre les recommandations PRISMA et utiliser un panel d\u2019outils statistiques pour mener \u00e0 bien cette m\u00e9ta-analyse compliqu\u00e9e. Une m\u00e9ta-r\u00e9gression avec effet al\u00e9atoire a \u00e9t\u00e9 utilis\u00e9e pour consolider les r\u00e9sultats, car de nombreux biais sont apparus parmi les articles retenus pour les analyses, \u00e0 savoir une tr\u00e8s forte h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 de r\u00e9sultats entre les publications et en plus un biais de publications significatif. Quelques \u00e9tudes ont notamment tir\u00e9 vers le haut ces r\u00e9sultats. Pour r\u00e9sum\u00e9, la m\u00e9thodologie est tr\u00e8s bonne mais prudence tout de m\u00eame sur les conclusions, m\u00eame si elles sont corrobor\u00e9es par de pr\u00e9c\u00e9dentes recherches.<\/p>\n<\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":16380,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[36],"tags":[342,343,344,325,345,346,347],"ppma_author":[442],"class_list":["post-16379","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-revue-de-presse","tag-cirrhose","tag-foie","tag-incidence","tag-meta-analyse","tag-prevalence","tag-revue","tag-thrombose-veineuse","author-marion"],"aioseo_notices":[],"authors":[{"term_id":442,"user_id":2,"is_guest":0,"slug":"marion","display_name":"HematoStat.net (M)","avatar_url":{"url":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2024\/01\/favicon-hematoStat.png","url2x":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2024\/01\/favicon-hematoStat.png"},"first_name":"HematoStat.net (M)","last_name":"","user_url":"","description":""}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/16379","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=16379"}],"version-history":[{"count":1,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/16379\/revisions"}],"predecessor-version":[{"id":18232,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/16379\/revisions\/18232"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=16379"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=16379"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=16379"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=16379"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}